▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Taylor Carmichael

TMFSaintCroix

Taylor Carmichael is a former attorney and filmmaker. He's the author of a line of murder mysteries, including Whodidit in the Supreme Court? and Whodidit With a Senator? The majority of what he knows about stocks he learned right here at the Motley Fool.

Recent Articles by Taylor Carmichael

diabetes-checkup

Feb 27, 2022 by Taylor Carmichael and Brian Withers

Up 700%, DexCom Stock Still Has Tons of Room To Run

The market for its products is huge.

GettyImages-1268513319

Feb 25, 2022 by Taylor Carmichael, George Budwell, and Patrick Bafuma

Don't Tell These 3 Healthcare Stocks There's a Bear Market

Many healthcare stocks have been outperforming the market averages this year. Here are three stocks our roundtable likes.

GettyImages-1294461674

Feb 25, 2022 by Taylor Carmichael

Why Right Now Is a Great Time to Buy Your First Crypto

The crypto pullback in 2022 is a wonderful opportunity to jump in and buy some coins.

GettyImages-clinicaltrial

Feb 23, 2022 by Taylor Carmichael

What Investors Can Learn From Biogen's Drug Approval That No One Wants

Will Aduhelm's controversial approval signal a new normal for clinical trials?

GettyImages-pharmaleb

Feb 23, 2022 by Taylor Carmichael

Will the COVID-19 Vaccine Speed Up Biotech Production?

The pandemic accelerated the pace of vaccine development and approval. Are faster approvals here to stay?

GettyImages-cryptoscreen

Feb 22, 2022 by Taylor Carmichael

Should Biotech Investors Care About Early Stage Clinical Trials?

Phase 1, phase 2, phase 3 -- what's the point of having so many clinical trials?

Joby PDF

Feb 20, 2022 by Taylor Carmichael

Aiming for a 100-Bagger? This Stock Has the Potential

Here's why I think Joby Aviation might be a massive winner over the next decade or two.

GettyImages-1126452641

Feb 20, 2022 by Taylor Carmichael, Jason Hall, and Matt Frankel

Why Netflix Stock Isn't Exciting Investors Right Now

Is the streaming giant's growth rate a red flag for investors?

GettyImages-1319763415

Feb 20, 2022 by Taylor Carmichael, Jason Hall, and Matt Frankel

This $1 Trillion-Potential Fintech Stock Is on Sale Right Now

Which fintech giant will hit the trillion-dollar mark first?

GettyImages-1288968370

Feb 20, 2022 by Taylor Carmichael and Jason Hall

Bull vs. Bear: DexCom Stock

Why are investors bullish on DexCom?

GettyImages-456509341

Feb 18, 2022 by Taylor Carmichael, George Budwell, and Patrick Bafuma

Scared of the Bear? Buy These 3 Healthcare Stocks

Healthcare is the smart play in this bear market. Here's why these three Fool.com contributors like Doximity, Amgen, and Novocure.

GettyImages-1255592762

Feb 10, 2022 by Taylor Carmichael, George Budwell, and Patrick Bafuma

3 Biotech Stocks That Are too Cheap to Ignore

Our Motley Fool roundtable likes Intercept Pharma, Viking Therapeutics, and Vir Bio.

GettyImages-1135776151

Feb 7, 2022 by Taylor Carmichael

Buy Your Winners: For Me That's Shopify, Novavax, and Sea

When the stock market crashes and your favorite stocks are getting killed, it's a good idea to add to your long-term winners.

GettyImages-1074631888

Feb 5, 2022 by Taylor Carmichael

Why Ankr Coin Might Go Sky High

A voice from the past, George Gilder, says that Google and Big Cloud are in big trouble. If he's right, Ankr might be the crypto that wins.

GettyImages-450806655

Feb 5, 2022 by Taylor Carmichael

A Trio of Tier 1 Cryptos Every Newbie Should Own

A lot of investors are scared of crypto and have not bought any. But for you newbies out there who are crypto curious, here's a guide to the tier 1 blockchains you definitely want to own.

GettyImages-1189508174

Feb 4, 2022 by Taylor Carmichael, George Budwell, and Patrick Bafuma

3 Amazing Stocks That Are 60% Off Their Highs

Here's why our roundtable is excited about Doximity, Novocure, and Affimed.

GettyImages-465050849

Feb 3, 2022 by Taylor Carmichael

Why Jack Dorsey's Opinion on Bitcoin Scares Me

Jack Dorsey's view on crypto is too limited and his focus on Bitcoin might cause trouble for his shareholders.

GettyImages-155351397

Feb 2, 2022 by Taylor Carmichael

Why Did the Market Drop So Much in January?

The Nasdaq fell nearly 9% last month, and it left many investors confused and scared.

GettyImages-1294461674

Jan 30, 2022 by Taylor Carmichael

Here's My Top Cryptocurrency to Buy in 2022

If things break right for this crypto, its value might soar far higher in the years ahead.

GettyImages-157326628

Jan 30, 2022 by Taylor Carmichael

Is MP Materials a Good Stock to Buy in 2022?

MP Materials is one mining stock worth watching.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services